hcv ns5a

ABT530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6.

Ombitasvir (ABT-267) is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a

Ruzasvir (MK-8408) is a novel and potent pan-genotypic inhibitor of hepatitis C virus NS5A with antiviral activity.

MK-8325 is a potent and orally available HCV NS5A inhibitor with replicative activity against a wide range of genotypes.MK-8325 has demonstrated bioavailability in in vitro and in vivo assays and has a favorable overall ADME profile.

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antivirals to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has not been convincingly implicated in cases of clinically apparent liver injury with jaundice.

Velpatasvir (GS-5816), also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

Elbasvir (MK-8742) is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

Samatasvir (ATOLIHZIXHZSBA-BTSKBWHGSA-N) is a pan-genotypic inhibitor of the HCV non-structural protein 5A.

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM) with a superior pan-genotypic profile, good pharmacokinetic properties, and favorable liver uptake.

MK-4882 is an effective inhibitor of HCV NS5A.

Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.

Ledipasvir (acetone) (GS-5885 acetone) is an HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Ravidasvir, also known as PPI-668 and ASC16, is a second-generation oral medication that exhibits potent and selective inhibition specifically targeting the nonstructural protein 5A (NS5A) of the Hepatitis C virus (HCV).

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the HCV NS5B RNA-dependent RNA polymerase, inhibiting recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 (IC50 < 28 nM).

NS5A-IN-2 (Compound 33) is a potent NS5A inhibitor with remarkable efficacy against HCV genotype 1b, increased activity against genotype 3a (GT 3a), and significant metabolic stability [1].

Daclatasvir Impurity C is an impurity found in Daclatasvir, a robust inhibitor of the HCV NS5A protein [1].

Ravidasvir, also known as PPI-668 and ASC16, is a second-generation, orally active, potent and selective HCV NS5A protein inhibitor.

AZD-7295 (A-689) is an NS5A inhibitor that may be used to treat HCV infection.

Yimitasvir (Emitasvir), an orally administered inhibitor targeting the hepatitis C virus's (HCV) nonstructural protein 5A (NS5A), shows potential for the exploration of chronic HCV infection treatments [1].

Yimitasvir diphosphate, also known as Emitasvir, is an orally-administered inhibitor of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A). It is utilized in the study of chronic hepatitis C virus infections [1].

SMCypIC31 is a non-peptide cyclophilin inhibitor that effectively inhibits peptidyl-prolyl cis trans isomerase (PPIase) (IC50: 0.1 μM). SMCypI C31 has a pan-genotypic effect against HCV, with an EC50 range of 1.20-7.76 μM against genotypes 1a, 1b, 2a, 3a and 5a HCV-SGRs and chimeric genotypes 2a 4a HCV-SGRs.

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].